Literature DB >> 26802605

The effect of mucoadhesive excipient on the nasal retention time of and the antibody responses induced by an intranasal influenza vaccine.

Shinji Saito1, Akira Ainai2, Tadaki Suzuki3, Norihiro Harada4, Yasushi Ami5, Yoshikazu Yuki6, Haruko Takeyama7, Hiroshi Kiyono6, Hideo Tsukada4, Hideki Hasegawa8.   

Abstract

INTRODUCTION: Recently, we reported that intranasal vaccination of humans with whole inactivated influenza vaccine in the absence of mucosal adjuvant induced neutralizing antibody responses in the serum and nasal mucus. The mucoadhesive excipient carboxy-vinyl polymer (CVP) increases the viscosity and therefore mucoadhesiveness of intranasal medicaments and is an authorized excipient in Japan. In the present study, we analyzed the effect of adding CVP on intranasal whole inactivated influenza vaccine antigen dynamics and antibody responses.
METHODS: Mice and nonhuman primates (NHPs) were intranasally administered the [(18)F]-radiolabeled vaccine and subjected to positron emission tomography analysis for 6h. Dendritic cells were stimulated in vitro with the vaccine mixed with or without a mucosal adjuvant (Ampligen) and/or CVP, after which the tumor necrosis factor (TNF)-α and interferon (IFN)-β levels in the supernatants were measured. Cynomolgus monkeys were immunized intranasally with the vaccine mixed with Ampligen and/or CVP and their vaccine-specific serum IgG and IgA titers were measured on days 0 and 33.
RESULTS: The vaccine was retained significantly longer in the nasal cavity of both mice and NHPs when it was delivered with CVP rather than PBS. Accumulation of the radiolabeled vaccine in the central nervous system was not detected in either model regardless of whether CVP was used. CVP only very weakly increased the TNF-α production of vaccine-stimulated dendritic cells. IFN-β production was not observed regardless of the presence or absence of CVP. CVP increased the vaccine-specific IgA antibody responses of the intranasally vaccinated cynomolgus macaques.
CONCLUSION: CVP increased intranasal retention of whole inactivated influenza vaccine, did not promote antigen redirection to the central nervous system, and improved mucosal antibody responses. The mechanism probably relates to its mucoadhesive properties rather than its ability to directly stimulate the immune system. Intranasal vaccines with CVP may be a promising candidate vaccine formulation for humans.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Influenza virus; Intranasal vaccine; Mucoadhesive excipient; Nonhuman primate; Real-time imaging; Vaccine dynamics

Mesh:

Substances:

Year:  2016        PMID: 26802605     DOI: 10.1016/j.vaccine.2016.01.020

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  3 in total

1.  Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.

Authors:  Hui Wu; Yuanyuan Bao; Xiang Wang; Dongming Zhou; Wenzhe Wu
Journal:  Hum Vaccin Immunother       Date:  2017-01-27       Impact factor: 3.452

2.  Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.

Authors:  Dorothy I Jones; Justin J Pollara; Brandi T Johnson-Weaver; Celia C LaBranche; David C Montefiori; David J Pickup; Sallie R Permar; Soman N Abraham; Massimo Maddaloni; David W Pascual; Herman F Staats
Journal:  J Virol       Date:  2019-06-28       Impact factor: 5.103

3.  Optimizing a Multi-Component Intranasal Entamoeba Histolytica Vaccine Formulation Using a Design of Experiments Strategy.

Authors:  Mayuresh M Abhyankar; Mark T Orr; Robert Kinsey; Sandra Sivananthan; Andrew J Nafziger; David N Oakland; Mary K Young; Laura Farr; Md Jashim Uddin; Jhansi L Leslie; Stacey L Burgess; Hong Liang; Ines De Lima; Elise Larson; Jeffrey A Guderian; Susan Lin; Aaron Kahn; Prakash Ghosh; Sierra Reed; Mark A Tomai; Karl Pedersen; William A Petri; Christopher B Fox
Journal:  Front Immunol       Date:  2021-06-25       Impact factor: 7.561

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.